Subscribe To

Price Alert Latest News Economic Calendar News

ARKG / Gene Editing Stock in ARKG Gets Buy Rating

2022 hasn't been a great year for all kinds of tech stocks, and certainly biotech has taken its fair share of lumps as interest rates have continued to dry up funding. That hasn't stopped the innovation that makes biotech such an appealing space, however. Read More

Demo Live Account See Partner Details

Content Topics

Gene

Editing

Stock

ARKG

Gets

Rating

Posted: Dec 14 2022, 19:16

Author Name: ETF Trends

ARKG News

By Zacks Investment Research
October 30, 2023

5 ETF Areas That Spooked Investors in October

After a downbeat September, October too remained volatile for Wall Street due to higher rates.

By The Motley Fool
October 16, 2023

Why Wall Street Thinks This Artificial Intelligence (AI) Stock Could Skyrocket 140% Over the Next 12 Months

This company uses AI to improve drug discovery for all of the 20 biggest biopharmaceutical companies. Even the most pessimistic analyst thinks the sto

By Kiplinger
August 24, 2023

Best Healthcare ETFs to Buy Now

The best healthcare ETFs patch investors into an area of the market that offers both defensive properties and long-term growth.

By The Motley Fool
July 27, 2023

Cathie Wood Is Buying Up Shares of This Beaten-Down Biotech. Should You?

Superstar investor Cathie Wood bought shares of Moderna over a period of two days this week. The biotech company may become a respiratory vaccine gian

By ETF Trends
April 24, 2023

ARKG: Smart Idea for Smart Advancements in Cancer Treatment

The cancer treatment/immuno-oncology market is expansive and ripe with potential for long-term healthcare investors. Predictably, there are significan

By ETF Trends
April 19, 2023

Biotech ETFs' Performance Deserves A Look

Biotech comes with a great many positive externalities for society, and can be a big positive for portfolios right now.

By Seeking Alpha
April 12, 2023

ARKG: A Probable Window Of Opportunity, Depending On Banks And The Fed

Cathie Wood's ARKG provides investors with an opportunity to take advantage of the billion-dollar genomics market. However, it has performed poorly co

By ETF Trends
April 10, 2023

Thematic Index Lineup Joins VettaFi and the Future Is Bright

A decade ago, when the ROBO Global Robotics & Automation Index ETF (ROBO) launched, the U.S. thematic ETF market was nascent, with only a handful of p

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.